AFP and hepatocellular carcinoma: Plasma biomarkers currently used clinically such as alpha-fetoprotein (AFP) and decarboxyloprothrombin (DCP), have low sensitivity and are insufficient for determination of the aggressiveness of HCC (Kim et al., 2017).